JP2011522864A5 - - Google Patents

Download PDF

Info

Publication number
JP2011522864A5
JP2011522864A5 JP2011512988A JP2011512988A JP2011522864A5 JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5 JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5
Authority
JP
Japan
Prior art keywords
use according
seq
medicament
amino acid
cac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011512988A
Other languages
English (en)
Japanese (ja)
Other versions
JP5481473B2 (ja
JP2011522864A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/057263 external-priority patent/WO2009150214A2/en
Publication of JP2011522864A publication Critical patent/JP2011522864A/ja
Publication of JP2011522864A5 publication Critical patent/JP2011522864A5/ja
Application granted granted Critical
Publication of JP5481473B2 publication Critical patent/JP5481473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011512988A 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 Expired - Fee Related JP5481473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6116308P 2008-06-13 2008-06-13
US61/061,163 2008-06-13
PCT/EP2009/057263 WO2009150214A2 (en) 2008-06-13 2009-06-12 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
JP2011522864A JP2011522864A (ja) 2011-08-04
JP2011522864A5 true JP2011522864A5 (enExample) 2012-07-05
JP5481473B2 JP5481473B2 (ja) 2014-04-23

Family

ID=41078180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512988A Expired - Fee Related JP5481473B2 (ja) 2008-06-13 2009-06-12 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体

Country Status (8)

Country Link
US (2) US8476408B2 (enExample)
EP (1) EP2310041B1 (enExample)
JP (1) JP5481473B2 (enExample)
CN (1) CN102065883A (enExample)
AU (1) AU2009256558B2 (enExample)
CA (1) CA2723270C (enExample)
MX (1) MX2010013677A (enExample)
WO (1) WO2009150214A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9651708B2 (en) * 2011-04-21 2017-05-16 Baker Hughes Incorporated Method of mapping reservoir fluid movement using gravity sensors
LT2790721T (lt) * 2011-12-15 2019-02-11 Millendo Therapeutics Sas Neacilinto grelino fragmentai, skirti naudoti preiderio-vilio sindromo gydymui
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014203074A2 (en) 2013-06-21 2014-12-24 Alize Pharma Sas Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
EP3719123A1 (en) 2014-04-29 2020-10-07 Mayo Foundation for Medical Education and Research Uses of butyrylcholinesterase variants having an enhanced ability to hydrolyze acyl-ghrelin
WO2018053216A1 (en) 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer
GB201918853D0 (en) * 2019-12-19 2020-02-05 Lund Lars H Methods of treatment

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5747296A (en) * 1992-05-11 1998-05-05 Corvas International, Inc. Method of detecting neutophil inhibitory factor mimics
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5695761A (en) * 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
WO1995024422A1 (en) * 1994-03-09 1995-09-14 Cortech, Inc. Bradykinin antagonist peptides incorporating n-substituted glycines
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US6627729B1 (en) 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
US5932548A (en) * 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000023469A2 (en) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
EP1286697A2 (en) 2000-05-17 2003-03-05 Eli Lilly And Company Method for selectively inhibiting ghrelin action
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
WO2002060477A1 (en) 2001-01-31 2002-08-08 Human Genome Sciences, Inc. Scaffolded fusion polypeptides, compositions for making the same and methods of using the same
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
WO2003051389A2 (en) 2001-12-18 2003-06-26 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2841097A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
AU2004249904A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7517269B2 (en) 2003-08-12 2009-04-14 Parvia Corp. Building element for constructing a modular substructure
CA2543507C (en) 2003-10-24 2012-05-01 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20070237775A1 (en) * 2004-07-14 2007-10-11 Eli Lilly And Company Anti-Ghrelin Antibodies
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
CA2587627A1 (en) * 2004-11-15 2006-05-26 Eli Lilly And Company Desacyl ghrelin antibodies and therapeutic uses thereof
US8653022B2 (en) 2006-03-28 2014-02-18 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
ES2538111T3 (es) 2007-05-31 2015-06-17 Alizé Pharma SAS Grelina no acilada como agente terapéutico en el tratamiento de trastornos metabólicos
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin

Similar Documents

Publication Publication Date Title
ES2875748T3 (es) Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que los comprende
JP2010031018A5 (enExample)
Lisco et al. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review
EA201691347A2 (ru) Терапия глатирамером ацетатом с низкой кратностью
JP2020062028A5 (enExample)
JP2013515009A5 (enExample)
JP2016516016A5 (enExample)
JP2011105728A5 (enExample)
JP2010532761A5 (enExample)
JP2011528333A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2013510169A5 (enExample)
JP2014532722A5 (enExample)
JP2009519949A5 (enExample)
JP2014506579A5 (enExample)
JP2006518750A5 (enExample)
WO2009150214A3 (en) Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
RU2007143510A (ru) Инсулиновые композиции
AU2021247258A1 (en) Anti-CD6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including COVID-19
JP2014500244A5 (enExample)
CN112423772A (zh) Rps2肽调节内皮细胞功能障碍的用途
WO2007029041A2 (en) Interferon lambda therapy for treatment of respiratory diseases
RU2014102752A (ru) Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты)
AU747885B2 (en) Treatment of disease states
JP2011105610A5 (enExample)